Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- HIV-Associated Lipodystrophy SyndromeCardiovascular Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-25
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 357
- Registration Number
- NCT00192634
- Locations
- 🇦🇺
QLD Health - AIDS Medical Unit, Brisbane, Queensland, Australia
🇦🇺John Hunter Hospital, Newcastle, New South Wales, Australia
🇦🇺The Centre Clinic, Melbourne, Victoria, Australia
D4T or Abacavir Plus Vitamin Enhancement in HIV-Infected Patients (DAVE)
- Conditions
- Acidosis, Lactic
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 80
- Registration Number
- NCT00143702
- Locations
- 🇨🇦
Positive Care Clinic, Toronto, Ontario, Canada
🇨🇦St. Paul's Hospital, Vancouver, British Columbia, Canada
Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-02-07
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 377
- Registration Number
- NCT00102960
A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy
- Conditions
- HIV Infections
- First Posted Date
- 2005-01-26
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 6
- Registration Number
- NCT00102206
- Locations
- 🇺🇸
Columbia IMPAACT CRS, New York, New York, United States
🇺🇸Chicago Children's CRS, Chicago, Illinois, United States
🇺🇸SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States
Blood Levels of Abacavir in HIV Infected Adolescents
- Conditions
- HIV Infections
- First Posted Date
- 2004-07-19
- Last Posted Date
- 2013-10-08
- Target Recruit Count
- 30
- Registration Number
- NCT00087945
- Locations
- 🇺🇸
Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States
🇺🇸Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States
🇺🇸Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States
Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 19
- Registration Number
- NCT00086359
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States
🇺🇸Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
- Conditions
- HIV InfectionInfection, Human Immunodeficiency Virus
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 866
- Registration Number
- NCT00085943
- Locations
- 🇨🇭
GSK Investigational Site, St Gallen, Switzerland
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 54
- Registration Number
- NCT00084149
- Locations
- 🇺🇸
University of Minnesota, ACTU, Minneapolis, Minnesota, United States
🇺🇸Beth Israel Med. Ctr., ACTU, New York, New York, United States
🇺🇸NY Univ. HIV/AIDS CRS, New York, New York, United States
Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis
- Conditions
- HIV InfectionsTuberculosis
- Interventions
- First Posted Date
- 2004-02-23
- Last Posted Date
- 2010-08-12
- Target Recruit Count
- 350
- Registration Number
- NCT00078247
- Locations
- 🇺🇬
Makerere University Medical School, Kampala, Uganda
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.